BR-6002 by Boryung Pharmaceutical for Cardiovascular Disease: Likelihood of Approval

BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Cardiovascular Disease.

Aug 28, 2023 - 20:00

BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Cardiovascular Disease.

Read the original article

Tags:

Previous Article

BR-6002 by Boryung Pharmaceutical for Gastric Ulcers: Likelihood of Approval

Vision for future micro-optical technology based on metamaterials

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

STAT+: Pharmalittle: We’re reading about Wegovy approved for heart risks, an ALS drug puzzle, and more

STAT+: Pharmalittle: We’re reading about Wegovy approve...

Mar 12, 2024

JPM Day 3 had a cautiously optimistic outlook

JPM Day 3 had a cautiously optimistic outlook

Jan 10, 2024

Novo Nordisk and NanoVation sign $600m deal in rare and cardiometabolic diseases

Novo Nordisk and NanoVation sign $600m deal in rare and...

Sep 20, 2024